Current and emerging therapies for pulmonary tuberculosis in adults
Abstract
Tuberculosis remains the biggest global killer from infectious causes, with an estimated 1.25 million deaths per year. The quadruple drug regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol has been standard therapy for 40 years, with good outcomes in patients with drug susceptible tuberculosis who are able to tolerate the drug regimen. However, the frequency of adverse drug reactions and emergence of drug resistant tuberculosis has created demand for new treatment strategies: there is now a surge in novel tuberculosis agents and regimens entering human trials. For decades, drug resistant tuberculosis required at least 18 months of second line and third line combination treatments that included injectable agents. In 2022, in response to a growing body of trial evidence, the World Health Organization (WHO) introduced six month and nine month all oral regimens for pulmonary drug resistant tuberculosis in specific settings. These encompass agents in the bedaquiline-pretomanid-linezolid/moxifloxacin regimen, as well as repurposed and novel agents such as clofazimine and delamanid. In addition, a large number of novel antimicrobial and host directed treatments are progressing to late stage clinical trials for tuberculosis, raising the prospect of shorter, more efficacious, and better tolerated treatments. This review summarises the agents and regimens recommended in the latest consolidated WHO treatment guidelines for tuberculosis (2025), including a synopsis of the…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.